Beyond antibiotic duration in acute cholangitis: system-level determinants after biliary drainage
Linda Pasta1, Fabrizio Bronte2, Emma Aragona2
1PRISMED B Corporation, Palermo, Italy. l.pasta@prismed.it.
Background:
The COBRA trial addresses whether antibiotic exposure can be safely reduced after adequate biliary drainage in acute cholangitis. We argue that antibiotic duration should be interpreted within the broader care pathway in which treatment is delivered, because source control, device management, host susceptibility, local microbiological ecology, and reliability of care processes may modify clinical outcomes.
Main Body:
Drawing on the Medical Research Council framework for complex interventions, we propose a system-level interpretation that complements, rather than replaces, the randomized comparison of antibiotic duration. A 24-month single-center quasi-experimental study in a gastroenterology unit, recently accepted for publication, provides hypothesis-generating support for this perspective: implementation of a standardized and traceable work-support intervention was associated with reductions in healthcare-associated infections, ward microbial pressure, and clinically expressed microbial burden. These findings do not establish causality or determine optimal antibiotic duration in acute cholangitis. To make care-pathway variability more explicit in future studies, we propose a Bundle Deviation Score based on six domains: timely diagnosis, timing of biliary drainage, adequacy of drainage and source control, antimicrobial strategy, device management, and standardized high-contact care. This contextual process measure could complement patient-centered outcome frameworks such as Desirability of Outcome Ranking by distinguishing treatment effects from variability in how care is delivered.
Conclusions:
The COBRA trial provides important evidence for antimicrobial stewardship after biliary drainage. Its interpretation and transferability may be strengthened by measuring the reliability of the broader care pathway alongside antibiotic duration. Prospective validation is required before the proposed Bundle Deviation Score can be used for clinical or research applications.
Related Concept Videos
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Cholecystitis
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Appendicitis-II: Diagnostic Studies and Management
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
Chronic Pancreatitis II: Collaborative Care
Assessment:
